High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors.

Thirty-one consecutive patients with relapsed or refractory GCT received an HDT schedule including carboplatin, the dose of which was adjusted to measured glomerular filtration rate. There was one HDT-associated death (3%), due to acute renal failure. The 3-year probability of overall and disease-fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyttelton, M. P., Newlands, E. S., Giles, C., Bower, M., Guimaraes, A., O'Reilly, S., Rustin, G. J., Samson, D., Kanfer, E. J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150058/
https://www.ncbi.nlm.nih.gov/pubmed/9635847
_version_ 1782144565145239552
author Lyttelton, M. P.
Newlands, E. S.
Giles, C.
Bower, M.
Guimaraes, A.
O'Reilly, S.
Rustin, G. J.
Samson, D.
Kanfer, E. J.
author_facet Lyttelton, M. P.
Newlands, E. S.
Giles, C.
Bower, M.
Guimaraes, A.
O'Reilly, S.
Rustin, G. J.
Samson, D.
Kanfer, E. J.
author_sort Lyttelton, M. P.
collection PubMed
description Thirty-one consecutive patients with relapsed or refractory GCT received an HDT schedule including carboplatin, the dose of which was adjusted to measured glomerular filtration rate. There was one HDT-associated death (3%), due to acute renal failure. The 3-year probability of overall and disease-free survival for 21 patients with primary refractory disease or responsive relapse was 60% and 42%, respectively, while none of ten patients with refractory relapse have survived disease free.
format Text
id pubmed-2150058
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-21500582009-09-10 High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors. Lyttelton, M. P. Newlands, E. S. Giles, C. Bower, M. Guimaraes, A. O'Reilly, S. Rustin, G. J. Samson, D. Kanfer, E. J. Br J Cancer Research Article Thirty-one consecutive patients with relapsed or refractory GCT received an HDT schedule including carboplatin, the dose of which was adjusted to measured glomerular filtration rate. There was one HDT-associated death (3%), due to acute renal failure. The 3-year probability of overall and disease-free survival for 21 patients with primary refractory disease or responsive relapse was 60% and 42%, respectively, while none of ten patients with refractory relapse have survived disease free. Nature Publishing Group 1998-05 /pmc/articles/PMC2150058/ /pubmed/9635847 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Lyttelton, M. P.
Newlands, E. S.
Giles, C.
Bower, M.
Guimaraes, A.
O'Reilly, S.
Rustin, G. J.
Samson, D.
Kanfer, E. J.
High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors.
title High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors.
title_full High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors.
title_fullStr High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors.
title_full_unstemmed High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors.
title_short High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors.
title_sort high-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150058/
https://www.ncbi.nlm.nih.gov/pubmed/9635847
work_keys_str_mv AT lytteltonmp highdosetherapyincludingcarboplatinadjustedforrenalfunctioninpatientswithrelapsedorrefractorygermcelltumouroutcomeandprognosticfactors
AT newlandses highdosetherapyincludingcarboplatinadjustedforrenalfunctioninpatientswithrelapsedorrefractorygermcelltumouroutcomeandprognosticfactors
AT gilesc highdosetherapyincludingcarboplatinadjustedforrenalfunctioninpatientswithrelapsedorrefractorygermcelltumouroutcomeandprognosticfactors
AT bowerm highdosetherapyincludingcarboplatinadjustedforrenalfunctioninpatientswithrelapsedorrefractorygermcelltumouroutcomeandprognosticfactors
AT guimaraesa highdosetherapyincludingcarboplatinadjustedforrenalfunctioninpatientswithrelapsedorrefractorygermcelltumouroutcomeandprognosticfactors
AT oreillys highdosetherapyincludingcarboplatinadjustedforrenalfunctioninpatientswithrelapsedorrefractorygermcelltumouroutcomeandprognosticfactors
AT rustingj highdosetherapyincludingcarboplatinadjustedforrenalfunctioninpatientswithrelapsedorrefractorygermcelltumouroutcomeandprognosticfactors
AT samsond highdosetherapyincludingcarboplatinadjustedforrenalfunctioninpatientswithrelapsedorrefractorygermcelltumouroutcomeandprognosticfactors
AT kanferej highdosetherapyincludingcarboplatinadjustedforrenalfunctioninpatientswithrelapsedorrefractorygermcelltumouroutcomeandprognosticfactors

Ejemplares similares